Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provigil Likely To Add Two New Claims; Broad Sleepiness Indication May Wait

Executive Summary

Cephalon expects that Provigil (modafinil) will receive an "approvable" letter on Oct. 20 for use in sleep disruption and circadian misalignment, CEO Frank Baldino said during a Sept. 25 conference call following an advisory committee review of expanded labeling for the narcolepsy agent

You may also be interested in...



Cephalon Launches Provigil Label Expansion; DTC Campaign Possible

Cephalon is launching its expanded Provigil label with a focus on educating physicians on sleepiness

Cephalon Launches Provigil Label Expansion; DTC Campaign Possible

Cephalon is launching its expanded Provigil label with a focus on educating physicians on sleepiness

Cephalon Preps For Provigil Label Expansion, Wins Bid For CIMA

Cephalon is enlarging its sales force to 500 reps in anticipation of FDA approval for an expanded wakefulness indication for Provigil, CEO Frank Baldino told analysts Nov. 3

Related Content

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel